Thanks 009 for clearing this up but I believe that was what I was stumbling apon- that Amgen seem to have patented the entire PCSK9 enzyme.
(
PCSK9) is an
enzyme encoded by the
PCSK9 gene in humans on
chromosome)
I am hopeful that the courts will disallow Amgen's patent based on its broad nature and possibility of trying to patent part of DNA functions.
Unilifes Teneo range all have Bluethooth available if the Pharma wants it, but if the treatment is for 16 weeks it may not be worth the cost of the Pharma supplying it (excess $200) as against the patient having to inject it (phobia/pain)
The longer term of injections the Teneo becomes cheaper on a cost per injection basis.
I tend to think this may be offered by Teneo with a full wearable the long term solution.
Thanks for your post as it looks like the luck pendulum might go our way.
The Sanofi and Regen share price did not spike at all on news release.
